Baseline Predictors of Clinical Response: A Post Hoc Analysis of the Ambition Trial

被引：0
|
作者：
Benza, Raymond [1 ]
Blair, Christiana [1 ]
Patel, Krishna [1 ]
Eads, Michael [1 ]
机构：
[1] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
来源：
CHEST | 2017年 / 152卷 / 04期
关键词：
D O I：
10.1016/j.chest.2017.08.1085
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：1052A / 1052A
页数：1
相关论文
共 50 条
  • [41] Post hoc analysis of the Exenatide-PD trial-Factors that predict response
    Athauda, Dilan
    Maclagan, Kate
    Budnik, Natalia
    Zampedri, Luca
    Hibbert, Steve
    Aviles-Olmos, Iciar
    Chowdhury, Kashfia
    Skene, Simon S.
    Limousin, Patricia
    Foltynie, Thomas
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2019, 49 (03) : 410 - 421
  • [42] Liraglutide 3.0 emg efficacy and safety by baseline BMI in the SCALE Diabetes trial: post-hoc analysis
    Hemmingsson, J. Udden
    Rosenstock, J.
    Davies, M.
    Bays, H.
    Cancino, A. -P.
    Skjoth, T. V.
    Aroda, V.
    DIABETOLOGIA, 2015, 58 : S311 - S311
  • [43] Improvements in COPD Symptoms with Umeclidinium/Vilanterol Analyzed by Baseline CAT Score: A Post Hoc Analysis of the EMAX Trial
    Vogelmeier, C.
    Boucot, I.
    Kerwin, E. M.
    Bjermer, L.
    Jones, P.
    Naya, I.
    Tombs, L.
    Compton, C.
    Lipson, D. A.
    Maltais, F.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [44] Effect of Deferoxamine on Outcome According to Baseline Hematoma Volume: A Post Hoc Analysis of the i-DEF Trial
    Wei, Chenchen
    Wang, Jeffrey
    Foster, Lydia D.
    Yeatts, Sharon D.
    Moy, Claudia
    Mocco, J.
    Selim, Magdy
    STROKE, 2022, 53 (04) : 1149 - 1156
  • [45] Improvements in COPD Symptoms With Umeclidinium/Vilanterol Analyzed by Baseline CAT Score: A Post Hoc Analysis of the EMAX Trial
    Vogelmeier, Claus F.
    Boucot, Isabelle
    Kerwin, Edward
    Bjermer, Leif
    Jones, Paul
    Naya, Ian
    Tombs, Lee
    Compton, Chris
    Lipson, David A.
    Maltais, Francois
    INTERNIST, 2022, 63 (SUPPL 3): : 353 - 354
  • [46] Baseline neurological deficit and argatroban plus alteplase in acute ischemic stroke: A post hoc analysis of ARAIS trial
    Cui, Yu
    Zhou, Zhong-He
    Sun, Xiao-Yu
    Luo, Na
    Chen, Hui-Sheng
    NEUROTHERAPEUTICS, 2024, 21 (05)
  • [47] Baseline Glucocorticoid-Related Toxicity Scores in Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial
    Patel, Naomi J.
    Fu, Xiaoqing
    Zhang, Yuqing
    Stone, John H.
    ACR OPEN RHEUMATOLOGY, 2023, 5 (01) : 51 - 58
  • [48] Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial
    Franek, Edward
    Gerstein, Hertzel C.
    Riddle, Matthew C.
    Nicolay, Claudia
    Hickey, Ana
    Botros, Fady T.
    Loo, Li Shen
    DIABETES OBESITY & METABOLISM, 2022, 24 (09): : 1753 - 1761
  • [49] Predictors of loss of asthma control in the Phase 2a INCONTRO trial: A post-hoc analysis
    Palmer, Robert
    Almquist, Joachim
    Hashemi, Mahdi
    Taib, Ziad
    Necander, Sofia
    Korsback, Katarina
    Aurell, Malin
    Asimus, Sara
    Delaney, Stephen
    Pardali, Katerina
    Gustafson, Per
    Sethi, Tariq
    Keeling, David
    Psallidas, Ioannis
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [50] Per-Treatment Post Hoc Analysis of Clinical Trial Outcomes With Tolvaptan in ADPKD
    Mallett, Andrew J.
    Perrone, Ronald D.
    Rangan, Gopala
    Hawley, Carmel
    El-Damanawi, Ragada
    Hiemstra, Thomas F.
    Arellano, Carolina Townsend
    Lee, Jennifer
    Torres, Vicente E.
    KIDNEY INTERNATIONAL REPORTS, 2021, 6 (04): : 1032 - 1040
12345